HC Deb 16 March 1987 vol 112 cc417-8W
Mr. Ashley

asked the Secretary of State for Social Services (1) what progress is being made with the development of a new whooping cough vaccine;

(2) when the decision was taken to postpone the trials of new whooping cough vaccines; on which vaccines there were to have been trials; for what reasons the trials were postponed; and if he will make a statement.

Mrs. Currie

[pursuant to her reply, 13 March 1987, c. 327]: A sub-committee of the Medical Research Council's

Table I
Percentage of total whole milk utilisation used for milk products by member state: 1979–85
Member State 1979 1980 1981 1982 1983 1984 1985
Belgium 72 72 72 83 75 73 73
Denmark 85 83 85 85 85 86 84
Germany 80 80 80 77 80 78 76
France 68 71 70 70 72 71 70
Ireland 75 74 73 75 77 79 79
Italy 62 61 62 63 62 61 61
Luxembourg 77 77 74 73 69 69 69
Netherlands 87 85 93 95 93 93 93
United Kingdom 50 51 52 50 51 49 49
Greece . . . . . . . . . . . . . .
. . not available.

Source: EC dairy facts and figures.

Table II
Percentage of each member state's production of butter and skimmed milk powder (SMP) sold into intervention: 1979–86
1979 1980 1981 1982 1983 1984 1985 19861
Member state Butter SMP Butter SMP Butter SMP Butter SMP Butter SMP Butter SMP Butter SMP Butter SMP
Belgium 29.7 6.2 3.7 10.0 0 8.1 3.8 19.4 24.7 44.8 17.5 33.1 14.6 17.5 26.4 49.4
Denmark 1.3 0.1 0 0 0 17.3 2.3 24.9 8.1 62.7 0.6 0 10.8 16.7 6.0 53.8
Germany 34.1 21.3 19.1 12.1 0.8 23.5 11.0 30.4 32.7 44.2 32.9 35.9 27.1 28.8 31.8 43.0
France 6.0 0 2.0 1.3 1.3 3.7 4.9 3.9 21.7 10.6 16.7 3.0 13.4 4.2 20.8 8.1
Ireland 0 6.1 2.3 0 0 5.2 9.7 50.2 27.4 43.9 24.2 9.4 44.0 0 48.4 21.1
Italy 0 0 0 0 0 0 0.3 0 1.6 0 0.9 0 0.8 0 1.0 0
Luxembourg 37.5 31.8 22.5 0 1.4 24.8 0 37.4 3.7 36.7 12.0 35.1 13.1 0 9.4 50.8

committee on development of vaccines and immunological products is supervising the development of a new whooping cough vaccine and is co-ordinating arrangements for clinical trials of that and similar vaccines.

Requirements under section 31 of the Medicines Act 1968 on the safe conduct of clinical trials must be satisfied before such trials can be carried out in the United Kingdom. Information about particular applications cannot be given for reasons of commercial confidentiality.